Show simple item record

dc.contributor.advisorMcBride, Ali
dc.contributor.advisorAbraham, Ivo
dc.contributor.authorTompkinson, Madeline
dc.date.accessioned2019-05-03T20:15:59Z
dc.date.available2019-05-03T20:15:59Z
dc.date.issued2018
dc.identifier.urihttp://hdl.handle.net/10150/632199
dc.descriptionClass of 2018 Abstracten_US
dc.description.abstractSpecific Aims: The number of newly approved agents continues to increase with over 800 new oncology agents in the pipeline and 25% of these being oral agents. Oral chemotherapy agents have advantages including patient convenience, prolonged drug exposure, and non-invasive administration. These advantages come at a premium that many patients cannot afford leading to change or therapy abandonment. Methods: This is a descriptive, non-experimental, cross-sectional study of healthcare professionals in hematology/oncology patient care across the United States. Data was collected using a 35-item online questionnaire to measure quality improvement areas when using oral chemotherapy agents. Results: Results of 503 survey respondents comprised of pharmacists (54%), physicians (5%), advanced practitioners (4%), nurses (10%), pharmacy administrators (15%), social workers (2%), and other professionals (9%). Treatment abandonment due to cost is seen by 46.6% of respondents. The most common agents abandoned due to cost included capecitabine, abiraterone, and palbociclib. Prior authorization delays occur in 1-2 patients weekly creating a 4-6 day wait to initiate therapy and 24.0% of respondents spend more than 30 hours weekly resolving these issues. The most utilized medication assistance programs include Manufacturer Assistance Programs, Disease-Based Foundations, and Manufacturer Co-Pay Cards. Conclusions: This survey addresses healthcare worker perspective on prevalence of and issues relative to chemotherapy and indicate a high incidence in abandonment of therapy, delay in therapy initiation, and significant resources allocated to issues associated with the cost of oral chemotherapy agents. Further evaluation is required to resolve issues in therapy and minimize impact on patient care.en_US
dc.language.isoen_USen_US
dc.publisherThe University of Arizona.en_US
dc.rightsCopyright © is held by the author.en_US
dc.subjectoral chemotherapyen_US
dc.subjecttreatment abandonmenten_US
dc.subjectoncology agentsen_US
dc.subjecthealthcare workersen_US
dc.subject.meshHealth Personnelen_US
dc.subject.meshAllied Health Personnelen_US
dc.subject.meshTreatment Adherence and Complianceen_US
dc.subject.meshQuality Improvementen_US
dc.subject.meshSurveys and Questionnairesen_US
dc.titlePerceptions of Healthcare Workers on the Cost and Safety of Oral Oncolytic Agents for Patients: A Survey of Healthcare Workeren_US
dc.typetexten_US
dc.typeElectronic Reporten_US
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen_US
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en_US


This item appears in the following Collection(s)

Show simple item record